Method for treating emotional numbness

ABSTRACT

An opiate antagonist or a pharmaceutically acceptable salt thereof is used to treat emotional numbness associated with Post Traumatic Stress Disorder and other psychopathologic conditions.

BACKGROUND OF THE INVENTION

1. Field of the Invention:

The present invention relates to the use of opiate antagonists to treatpsychopathologic conditions, more particularly, the use of opiateantagonists to treat emotional numbness associated with Post TraumaticStress Disorder (PTSD) and other psychopathologic conditions.

Emotional numbness is conceptualized as a biopsychological response toextreme emotional or physical trauma.

2. Description of the Related Prior Art:

At this time, there is no pharmacological treatment available for thepsychiatric condition of emotional numbing.

The principal feature of emotional numbness is a person's subjectiveexperience of the inability to feel emotions, and is accompanied by alack of care and concern for self and others. When numbness is profoundno feeling can be experienced and the person takes on a "wooden"expressionless and lifeless appearance. Numb individuals are generallyunresponsive to the environment and they are socially withdrawn.Unresponsiveness to the environment is a composite disturbancerepresenting a diminished level of mental alertness and awareness and aloss of interest in the outside world. Numb individuals do notexperience an empathic bond or a sense of relatedness to others. Insocial situations they tend to feel alienated and apart. Emotionalnumbness is frequently associated with numbness and/or paresthesias ofthe body and feelings of heaviness or paralysis. Severe numbness isaccompanied by a profound impairment of concentration and memory with anamnesia for events occurring during the numb state. Informationprocessing of any kind may be severely impaired. When emotional numbnessis severe and prolonged, it is usually accompanied by a lack ofmotivation, interest or pleasure in life's activities. Numb individualsare thus emotionally, mentally, psychologically and socially impaired.They are less able to deal with stresses of any kind--especiallyreminders of their past traumatic experiences. They tend, therefore, toavoid thoughts or feelings and activities or situations which mightactivate recollections of the original traumatic event(s). The oneexception to this last statement is the tendency for some numbedindividuals to at times actively seek out exciting or (very) dangerousactivities in order to overcome their numbness and to experience feelingalive (see below).

The presence of numbing is evaluated clinically as part of thepsychiatric diagnosis of PTSD. No independent laboratory tests currentlyexist to identify the presence or absence of numbing. Numbing (andavoidance) is one of four categories of psychiatric disturbance thatmust be fulfilled for an individual to receive the diagnosis of PTSD.The American Psychiatric Association's Diagnostic Statistical Manual's(DSMR III-R) definition of numbing (and avoidance) includes seven items,any three of which have to be present for that category (numbing andavoidance) to be fulfilled. Emotional numbness is specificallyrepresented by two of seven items. One item describes the presence of arestricted range of affect, e.g., the inability to have loving feelings.A second item describes a marked diminished interest in significantactivities. Numbing is defined by this Manual as "persistent avoidanceof stimuli associated with the trauma or numbing of generalresponsiveness (not present before the trauma), as indicated by at leastthree of the following:

(1) efforts to avoid thoughts or feelings associated with the trauma

(2) efforts to avoid activities or situations that arouse recollectionsof the trauma

(3) inability to recall an important aspect of the trauma (psychogenicamnesia)

(4) markedly diminished interest in significant activities (in youngchildren, loss of recently acquired developmental skills such as toilettraining or language skills)

(5) feeling of detachment or estrangement from others

(6) restricted range of affect, e.g., unable to have loving feelings

(7) sense of foreshortened future, e.g., does not expect to have acareer, marriage, or children or a long life."

The above conditions are clinical conditions exhibited by an individualwhich are criteria a health care provider would look to during thepsychiatric diagnosis.

Emotional numbing is primarily a subjective complaint. Emotionalnumbness can vary along three parameters: duration, severity, and socialcontext. Numbness can be experienced for minutes, hours, days, months oryears on a continuous or intermittent basis. A person who has severe orprofound emotional numbing does not have any feelings at all. In a lesssevere case, emotions associated with high levels of physiologicalarousal may be experienced: e.g., rage, fear, and vulnerability.However, tender affectionate feelings are not felt. For periods of time,some less severely numbed individuals may be able to experience love andconcern towards a specific individual(s). This may be a child, trustedspouse or fellow survivor of a traumatic episode.

Emotional numbing may be accompanied by a physical experience ofheaviness or paralysis of the body, pins and needles, tingling ornumbness of parts of the body, feelings of unreality, alienation, anddetachment from others. Cognitive disturbances can include mentalconfusion, amnesia, impaired concentration, indecisiveness, inability toplan future actions, and a paralysis of will. These cognitivedisturbances may occur independent of the level of physiological arousalor distress; forgetfulness, disorientation, or confusion can occurwithout any apparent preceding increase in stress or anxiety.

Some patients are not able to make the distinction between the mentalstates of numbness and depression. Impaired cognitions, including anabsence of self awareness, may interfere with an individual's ability todistinguish between numbness and depression. Other individuals mayfrequently shift between states of depression and numbness which makesit difficult for them to distinguish their subjective experiences.Numbness and depression also share certain symptoms including impairedconcentration and memory and lack of interest and pleasure in life'sactivities. Emotional numbness should be distinguished from depression.Emotional numbness denotes an absence of feelings (including those ofdepression and sadness). In contrast to a depressed person, a numbedindividual lacks feelings of regard, concern, caring or empathy forhimself/herself and others. Common terms which traumatized persons useto describe this numb state of mind include: shutdown, numb, ice cold,hollow, dead, empty and no feelings, care or concern for anyone oranything. Family members commonly regard relations who are numb as beingcold, heartless, and emotionally unresponsive. A profoundly numbindividual has a wooden facial expression rather than one that isdepressed. Very occasionally the emotionally numbed individual mayappear to be angry or sad to others, yet respond with bewilderment ordenial when questioned about his/her look of anger or sadness.

Numbed persons may learn to role play appropriate behavioral responsesin family and social settings even though they continue to have nofeelings. When questioned, these individuals may relate what theythought they should have felt based on their inferences and judgmentsabout the situation rather than what they actually experienced.

The mental state of emotional numbness is a disabling condition for thetraumatized victim and his or her family members. Numbness interfereswith a person's ability to enjoy and participate in life's activities(work, intimacy, sex, etc.) and with the individual's ability to respondwith genuine affection, interest or concern about anybody or anything,which can oftentimes lead to marital and family discord. Although anumbed individual may be less likely to respond emotionally to mostsituations, the same individual may be more likely to lash out than toexercise restraint once enraged because of his/her indifference to theconsequences of his/her actions. In addition, rage can also precipitateor intensify the numb response.

When numbed individuals do experience negative emotions such as rage,bitterness, hostility or betrayal, these mood states continue forextended periods of time. However, emotions that are positively feltdecay rapidly and evaporate.

Some individuals with emotional numbing may seek out sensation andrisk-taking activities such as skydiving, racing cars, gambling, drugabuse, self-inflicted pain, etc. in an effort to escape the deadeningeffect of numbness These activities can assume a compelling addictivedrive accompanied by intense feelings of craving.

Endogeneous opiates (endorphins) are actively produced in the centralnervous system (CNS) in response to stress. Endorphins represent one ofthe primarily major inhibitory neurotransmitter systems, inhibiting therelease of other neurotransmitters, both in the CNS and in theperipheral organs. Endorphins can inhibit the neural transmission ofsensory information in the spinal cord. Endorphins have been stronglyimplicated in the experimental paradigm of stress induced analgesia.Conditioned stress induced analgesia is believed to be specificallyendorphin dependent.

Exogenous opiates demonstrate a variety of effects on the mood andbehavior of animals and man depending on dose, chronicity, method, siteand timing of administration (in relation to exposure to stress).Responses may vary from calm sedation and euphoria to dysphoria andagitation. Opiates are well known for their ability to cause mentalconfusion, apathy and reduction of anxiety associated with pain.

The limbic system of the CNS is where emotions, motivations andinterests are processed and modulated. It is a region densely populatedwith opiate receptors. In PTSD endorphins are postulated to shut downthe processing of emotional experiences and motivational systems whichleads to numbness and loss of interest.

The hippocampus is a structure within the limbic system which isconsidered important for memory processing, including the consolidationand establishment of long term memory. Amnesia is classically associatedwith damage to the medial temporal brain region, especially thehippocamus formation. This region, in turn, has extensive projections tospecific sensory modality pathways and polymodal areas in the neocortexwhere long term memory storage probably occurs. These areas are alsodensely occupied by opiate receptors. Opiates have also been found to becapable of inducing amnesia in experimental animals. Excessive secretionof endorphins in these regions are hypothesized to lead to symptoms ofmental confusion, disorientation and amnesia.

States of numbness are similarly postulated to occur in otherpsychopathological conditions. These include affective disorders such as"masked" depression and severe or psychotic depression. The lattercondition is generally unresponsive to antidepressants but is responsiveto electric shock therapy. Opiate antagonist medication provides analternative to that form of intervention for many of these individuals.A number of psychological and clinical states may produce apathy which,by definition, includes the absence of emotions. When apathy is not theresult of organic degeneration of the central nervous system it shouldsimilarly be considered for opiate antagonist treatment. Severelyanxious individuals and those with hypochondriacal and psychosomaticconditions may experience numbness. Alexithymia, a condition in whichindividuals are unable to describe their feelings verbally, is observedin persons with the diagnosis of PTSD and in persons with psychosomaticdisorders. It is postulated that a percentage of individuals withalexithymia manifest this difficulty as a result of emotional numbness.Furthermore, schizophrenic conditions in which negative symptomsincluding apathy predominate also experience emotional numbness. In allthese conditions, numbness represents an extreme biopsychologicalresponse to the stress of emotional overload so that the emotionalexperience is profoundly dampened down or turned off and the expenditureof metabolic energy is reduced. The numb state, however, createsadditional problems of its own (as described above). Numbness can becomethe principal response to any nonspecific situation in which anindividual feels vulnerable and/or unable to cope. This is especiallytrue of the PTSD population, where the numb response is likely to becomea chronic and persistent problem.

Nalmefene is a known narcotic antagonist.

U.S. Pat. Nos. 3,814,768 and 3,896,226 both to Fishman disclosenalmefene and its pharmaceutically acceptable salts per se and as acomponent in narcotic antagonist compositions, respectively.

Compounds related to nalmefene, i.e., having the same pentacyclicnucleus, including naloxone, naltrexone, nalbuphine, thebaine, etc., arealso known and are used to treat mental illness.

U.S. Pat. No. 4,388,324 to Horrobin discloses the use of certain opiateantagonists, e.g., naloxone to enhance the prostaglandin (seris 1)levels which are suggested to thereby indirectly influence schizophreniaand depression.

U.S. Pat. No. 3,717,643 to Archer discloses the use of certain morphinederivatives as central nervous system stimulants. U.S. Pat. No.3,299,072 to Bartels-Keith discloses the use of certain thebainederivatives for the same purpose.

U.S. Pat. No. 3,282,050 to Buckett et al. discloses the use of certainmorphine derivatives as tranquilizers or psychosedatives.

U.S. Pat. Nos. 4,154,142 and 4,511,570 disclose the use of a particularnormorphone derivative to treat hyperkinetic children and senile adults,respectively.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a novel method fortreating emotional numbness associated with PTSD and otherpsychopathologic conditions.

This objective and other objectives are achieved by providing a methodcomprising administering to a patient in need thereof an effectiveamount of an opiate antagonist or a pharmaceutically acceptable saltthereof, preferably in combination with a pharmaceutically acceptablecarrier. Preferably, the opiate antagonist is an opiate antagonisthaving a pentacyclic nucleus, most preferably, nalmefene, naloxone,naltrexone, nalbuphine, or thebaine. Preferably, nalmefene isadministered orally in an initial dosage of about 0.5 to 1.0 mgms.b.i.d. for about one week, followed by a dosage of about 1.0 to 5.0mgms. b.i.d. for about one week, followed by a dosage of about 5.0 to10.0 mgms. b.i.d. for about one week, followed by a dosage of about 10.0to 20.0 mgms. b.i.d. for about one week. The dosage is increased byabout 10.0 to 20.0 mgms. every week thereafter until the patient hasachieved a numb-free state.

Symptoms related to the emotional numbness, i.e., conditions exhibitedby an individual which are a by-product of the emotional numbness, suchas somatic numbing, pins and needles, lack of empathy, mental confusion,amnesia, loss of interest and compulsive sensation seeking behavior arereduced by the method of the invention. The emotional numbness itselfmay be associated with one or more psychopathologic conditions, such asPTSD, depression, hypochondria, anxiety, a psychosomatic disorder ornegative symptoms of schizophrenia, or the emotional numbness may beassociated with one or more physical insults to the central nervoussystem such as a closed head injury or a cerebral vascular accident.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

In general, the present invention relates to the use of opiateantagonists, for the treatment of emotional numbness associated withPTSD and other psychopathologic conditions.

It has been discovered that when emotional numbness is overcome inaccordance with the method of the invention, certain secondarycharacteristics or symptoms related to or derived from the emotionalnumbness begin to disappear or at least begin to lessen significantly.In other words, when emotional numbness is successfully treated, thenother conditions or symptoms associated with it are also treated. Someof these by-product conditions or symptoms of emotional numbnessinclude, but are not limited to, somatic numbing, pins and needles, lackof empathy, mental confusion, amnesia, loss of interest, and compulsivesensation seeking behavior. The emotional numbing itself may beassociated with PTSD or any other psychopathologic condition including,but not limited to, depression, hypochondria, anxiety, a psychosomaticdisorder and negative symptoms of schizophrenia. Moreover, the emotionalnumbness may be associated with any of various physical insults to thecentral nervous system, such as, but not limited to, closed headinjuries and cerebral vascular accidents.

Although any suitable opiate antagonist may be employed, an opiateantagonist having a pentacyclic nucleus, such as nalmefine, naloxone,naltrexone, nalbuphine or thebaine, is preferred. Of these opiateantagonists, nalmefene is most preferred.

Nalmefene (6-methylene-6-desoxy-N-cyclopropylmethyl-14-hydronormorphine)is derived by the Wittig reaction from naltrexone. See Hahn et al., J.Med. Chem. 18, 259 (1975). See also U.S. Pat. Nos. 3,814,768 and3,896,226, both disclosures of which are hereby incorporated byreference. Suitable nalmefene for use in the method of the invention iscommercially available in its hydrochloride salt form from Ivax, 8800Northwest 36th Street, Miami, Fla., 33178. Nalmefene has the followingformula: ##STR1##

While not wishing to be bound by theory, it is believed that theexocyclic methylene group at position 6 of the molecule enhances oralbioavailability and potency of the drug by blocking one of its sites ofmetabolism.

This compound is particularly effective by the oral route and is alsoeffective when administered parenterally, although any suitable routemay be employed. The compound is preferably combined (mixed) with apharmaceutically acceptable inert carrier for easy ingestion, andbecause nalmefene has a high potency in small dosages. Suitable inertcarriers include, but are not limited to, water, milk optionally withsugar and/or starch, natural and synthetic fruit juices, such as orangejuice, grapefruit juice, grape juice, pineapple juice, lemon juice andprune juice, and sweetened beverages such, for instance, as flavoredwater with or without carbonation. If the compound is to be administeredorally, one of the above carriers is desirable. If the compound is to beadministered parenterally, distilled water is a desirable carrier. Thecompound also may be administered rectally by incorporation in astandard suppository. Other routes of administration and suitablepharmaceutically acceptable carriers therefor will be apparent to oneskilled in the art.

The method of the invention is recommended for any individual who hasPTSD and/or other psychopathologic conditions noted above, in whomnumbness is persistent and interferes with that person's ability toenjoy life's activities and to relate to significant others.Administration of an opiate antagonist in accordance with the inventionis preferably instituted at the lowest possible oral dose to be followedby weekly incremental doses until numbing is reversed. Benzodiazepines,clonidine and other medications used in the treatment of opiatewithdrawal symptoms will generally be needed to control any resultingdistresses (e.g., increased symptoms of anxiety, palpitations, insomnia,abdominal pain, and diarrhea) until adequate opiate blockade isachieved. Specific dosages are a function of the intensity andpersistence of numbing, the degree of continuing external stressors andthe intensity of associated levels of physiological arousal. The finaldose to reverse the effect of numbing will be significantly higher thanthe dose used to precipitate withdrawal reactions in a narcotic addict.Opiate blockade in the PTSD individual preferably is maintained at ahigh dose level because endorphins are constantly being manufacturedwithin the brain as part of a conditioned neurochemical response.Maintenance dosage is preferably continued for at least one year beforea trial of gradual reduction is attempted. During that period, theindividual should have shown an ability to consistently relate tosignificant others and to experience feelings rather than numbness.

Dosage changes may be instituted relatively quickly as long as thepatient is followed carefully on a weekly basis and is informed inadvance of temporary increases of emotional and physical symptoms.Patients who are administered clonidine should be provided with themeans to take their blood pressure on a regular basis.

Preferably, in the method of the invention, the patient is started onnalmefene at about 0.5 to 1.0 mgm. b.i.d., raised to 1.0 to 5.0 mgms.b.i.d. the following week, then to 5.0 to 10.0 mgms. b.i.d. the thirdweek, and to 10.0 to 20.0 mgms. b.i.d. the fourth week, with 10.0 to20.0 mgm. increases per week thereafter. Most preferably, an opiateantagonist is started at about 0.5 mgm. b.i.d., raised to about 1 mgm.b.i.d. the following week, then to 5 mgms. b.i.d. the third week and toabout 10 mgms. b.i.d. the fourth week, with about 20 mgm. increases perweek thereafter.

Patients should keep daily logs of their numb state, the presence orabsence of nightmares, flashbacks, intrusive thoughts, startleresponses, and their respective intensities. Weekly records should bekept of the patient's level of anxiety and mood states. Patients withsignificantly higher baseline levels of anxiety and who have to bemaintained on mild tranquilizers will require more careful supervision,larger doses of a tranquilizer and higher doses of opiate antagonistbefore their numbness is reversed. Some individuals may require doses ofopiate antagonist that would be greater than 100 mgms. b.i.d. It shouldbe emphasized that in the process of increasing the dose of opiateantagonist, any symptom associated with PTSD may worsen before itimproves. As the dose of the drug is increased, patients will commonlyexperience increased feelings of emotional vulnerability. Some symptomsin some individuals may persist for a longer period of time before theyreverse. This drug may make some individuals temporarily more numb,especially when administered to persons who are anxious. It will beunderstood by those skilled in this field that the dosage may be variedto accommodate individual needs, reactions or circumstances. Also,clinically obese individuals should not be administered the drug becausethey experience intensely adverse reactions of rage and/or anxiety atvery low doses. In general, a significantly large dose increase isrequired to go from a good to a 100% no-numbness response.

The invention will be more fully understood by reference to thefollowing examples:

EXAMPLE 1

John Doe is a 44-year old married Vietnam combat veteran who served as amedic during the war. He was exposed to several life-threateningexperiences in addition to his emergency medical treatmentresponsibilities. Mr. Doe has been emotionally numb since his dischargefrom service in Vietnam. He began to experience nightmares andflashbacks after a visit to the Washington Vietnam Memorial War in 1984.Subsequent to that date, Mr. Doe was diagnosed to have PTSD as a resultof his exposure to trauma in the Vietnam War.

John Doe evidenced persistent numbing on a daily basis prior to startingon nalmefene 1 mgm. b.i.d. Baseline subjective level of tension wasrated to be moderate. Mr. Doe was not on any tranquilizer. The dosage ofnalmefene was increased 2 mgms./day, twice a week. The patientcomplained of episodic symptoms of anxiety, restlessness, irritability,abdominal pain and insomnia until the dosage was increased to 28 mgms.b.i.d. Symptoms either worsened or improved with dosage increases.Emotional numbness showed considerable variation from day to day with agradual increase in the number of numb-free days. Mr. Doe was able tomaintain a relatively symptom (anxiety) free state with occasionallimited periods of numbness for one month on a dose of 28 mgms. b.i.d.Anxiety symptoms up to that dose had been controlled with a mildtranquilizer and clonidine 0.1 mgm. as needed. The patient becameseverely numb again when he was told that his wife would require majorsurgery. Nalmefene was increased once again to 2 mgms./day on twice aweek basis. Surgery was successful but the patient continued toexperience considerable numbness with feelings of vulnerability anddiminished sex drive. Mr. Doe's condition began to improve at the doseof 41 mgms. b.i.d. At that time, he was informed that his mother had arecurrence of cancer. Numbness once again significantly worsened withthe appearance of panic attacks, restlessness, social withdrawal,insomnia, and impaired concentration and memory. His conditionstabilized once again at a dose of 47 mgms. b.i.d. with only occasionalrestless sleep and intermittent anxiety. It should be noted that thispatient's nightmares and flashbacks essentially disappeared once he wasstarted on nalmefene at the beginning of the protocol. These symptomsbriefly returned when his condition deteriorated during his wife'sconvalescence from surgery. The dosage was increased 4 mgms./day from 47mgms. b.i.d. to 55 mgms. b.i.d., and then increased by 10 mgms./day from55 mgms. to 60 mgms. b.i.d. An additional major stressor experiencerequired raising the dose to 80 mgms. bid. This patient has maintained anumb-free state with no anxiety symptoms or complaints of sluggishnessat this dosage.

EXAMPLE 2

Jane Smith is a 38-year old woman married to a disabled Vietnam combatveteran who has the diagnosis of PTSD. Mrs. Smith's mother and youngerbrother are both psychotic. They live on the second floor of thetwo-family house in which the Smith couple reside. Jane Smith has alwaysbeen regarded as the most resilient and responsible member of thefamily. She, in turn, has always considered it to be her obligation tolook after the needs of the other family members. Mrs. Smith was inmarital counseling with her husband when she began complaining ofincreasing emotional numbness and an inability to care for others. Mrs.Smith was administered Trexan (naltrexone hydrochloride), 25 mgms. perday for one week after baseline liver enzymes were found to be normal.She then reported feeling more alert, but experienced intermittentsymptoms of light-headedness and interrupted sleep. Trexan was increasedto 50 mgms. per day during the second week. She then reported feelingmore energetic, had mild anxiety, diminished sluggishness and increasedaccess to her emotions, especially feelings of anger and resentmenttowards family members for their persistent demands. Mrs. Smith's dosagewas increased on the third week, for the last increase to 75 mgms. perday. She reported feeling calmer, more confident, and no longer numb.Sleep was restful and no longer interrupted. It was decided to maintainher on that dose for 3-6 months in order to enable Mrs. Smith to dealmore confidently with her family members. During that period of time,Mrs. Smith became depressed. She was then begun on a tricyclicanti-depressant. Mrs. Smith showed a very positive response to thetricyclic anti-depressant, which would not have helped her during thenumb state.

Although the present invention has been described in relation toparticular embodiments thereof, many other variations and modificationsand other uses will become apparent to those skilled in the art. It ispreferred, therefore, that the present invention be limited not by thespecific disclosure herein, but only by the appended claims.

What is claimed is:
 1. A method for treating emotional numbness,comprising administering to a patient in need thereof an effectiveemotional numbness reversing amount of an opiate antagonist or apharmaceutically acceptable salt thereof.
 2. The method of claim 1,wherein the opiate antagonist is an opiate antagonist having apentacyclic nucleus.
 3. The method of claim 2, wherein the opiateantagonist is selected from the group consisting of nalmefene, naloxone,naltrexone, nalbuphine and thebaine.
 4. The method of claim 3, whereinthe opiate antagonist is nalmefene.
 5. The method of claim 3, whereinthe opiate antagonist is naloxone.
 6. The method of claim 3, wherein theopiate antagonist is naltrexone.
 7. The method of claim 3, wherein theopiate antagonist is nalbuphine.
 8. The method of claim 3, wherein theopiate antagonist is thebaine.
 9. The method of claim 1, wherein theadministration is oral administration.
 10. The method of claim 1,wherein the effective amount comprises an initial dosage of about 0.5 to1.0 mgms. b.i.d. for about one week, followed by a dosage of about 1.0to 5.0 mgms. b.i.d. for about one week, followed by a dosage of about5.0 to 10.0 mgms. b.i.d. for about one week, followed by a dosage ofabout 10.0 to 20.0 mgms. b.i.d. for about one week, with about 10.0 to20.0 mgm. increases in dosage per week thereafter until the patient hasachieved a numb-free state.
 11. The method of claim 10, wherein theeffective amount comprises an initial dosage of about 0.5 mgms. b.i.d.for about one week, followed by a dosage of about 1 mgm. b.i.d. forabout one week, followed by a dosage of about 5 mgms. b.i.d. for aboutone week, with about 20 mgm. increases in dosage every week thereafteruntil the patient has achieved a numb-free state.
 12. The method ofclaim 1, wherein the opiate antagonist or pharmaceutically acceptablesalt thereof is administered in combination with a pharmaceuticallyacceptable carrier.
 13. The method of claim 12, wherein the carrier isselected from the group consisting of water, milk, fruit juice andsweetened beverage.
 14. The method of claim 1, wherein the emotionalnumbness is associated with at least one psychopathologic condition. 15.The method of claim 14, wherein the psychopathologic condition is atleast one psychopathologic condition selected from the group consistingof post traumatic stress disorder, depression, hypochondria, anxiety, apsychosomatic disorder, depersonalization disorder and negative symptomsof schizophrenia.
 16. The method of claim 1, wherein the emotionalnumbness is associated with at least one physical insult to the centralnervous system of the patient.
 17. The method of claim 16, wherein thephysical trauma is at least one physical trauma selected from the groupconsisting of closed head injury and cerebral vascular accident.